Novartis ( (NVS)) provided an update.
Novartis announced the success of a phase 3 STEER study of the intrathecal onasminogen apiparvovec (OAV101 IT) in the treatment of spinal muscular atrophy (SMA) type 2 in children and young adults. The study showed an increase in motor function, displaying the effectiveness and safety of the treatment compared to a placebo control. Novartis plans to seek regulatory approval in 2025, which could enhance treatment options for spinal muscular atrophy patients and strengthen the company’s position in gene therapy innovation.
More about Novartis
Novartis AG is a global healthcare company headquartered in Basel, Switzerland, specializing in innovative medicines, eye care products and generic pharmaceuticals. The company focuses on developing treatments for various diseases, leveraging its expertise in biology and technology to address unmet medical needs.
Price performance since the beginning of the year: -0.17%
Average trading volume: 1,126,668
Artistic Sentiment Consensus Rating: He catches
Current market value: $195.1 billion
For an in-depth examination of NVS stock, go to TipRanks stock analysis page.
https://media.zenfs.com/en/tipranks_452/bbad1dd12cc6ba90ddd83aeee03f1aae
Source link